Oral beclomethasone dipropionate treatment for gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Oral beclomethasone dipropionate treatment for gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation - Oral beclomethasone dipropionate treatment for gastrointestinal GVHD after allo-HSCT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027026

Enrollment

Registered

2017-04-17

Start date

2017-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with symptoms of acute gastrointestinal GVHD after allo-HSCT

Interventions

administration of oral beclomethasone 1-2capx4 /day

4-8mg/day about 50 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Who are admitted to our hospital for the purpose of allogeneic hematopoietic stem cell transplantation , and cases in which data can be collected for research.

Exclusion criteria

Exclusion criteria: 1. Cases who can not be collected data. 2. Patients whose research managers judged inappropriate as subjects. 3. Patients who had requested refusal to investigate.

Design outcomes

Primary

Measure	Time frame
Whether beclomethasone improve GI GVHD grade or reduce the need for systemic glucocorticoid treatment, at two weeks after administration.	—

Countries

Japan

Contacts

Public ContactNorina Tanaka

Tokyo Women's Medical University Department of Hematology

tanaka.norina@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026